Literature DB >> 17155913

Combination of active and inactive siRNA targeting the mitotic kinesin Eg5 impairs silencing efficiency in several cancer cell lines.

Etienne Formstecher1, Celine Reverdy, Mickael Cholay, Cecile Planquette, Virginie Trouplin, Heike Lehrmann, Sandra Aresta, Alessandra Calabrese, Khalil Arar, Laurent Daviet, Frederic Colland.   

Abstract

Gene silencing by RNA interference (RNAi) has proven to be a powerful tool for investigating gene function in mammalian cells. Combination of several short interfering RNA (siRNA) targeting the same gene is commonly used to improve RNA interference. However, in contrary to the well-described mechanism of RNAi, efficiency of single siRNA compared to pool remains poorly documented. We addressed this issue using several active and inactive siRNA targeting Eg5, a kinesin-related motor involved in mitotic spindle assembly. These siRNA, used alone or in combination, were tested for their silencing efficiency in several cancer cell lines. Here we show that presence of inactive Eg5 siRNA in a pool dramatically decreases knockdown efficacy in a cell line- and dose-dependent manner. Lack of inhibition by unrelated siRNA suggests that a competition may occur during siRNA incorporation into RNA-induced silencing complexes (RISCs) along with the target mRNA. Altogether, our results, which need to be confirmed with additional inactive siRNA, indicate that combination of siRNA may not increase but instead decrease silencing efficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155913     DOI: 10.1089/oli.2006.16.387

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  8 in total

1.  Competition between small RNAs: a quantitative view.

Authors:  Adiel Loinger; Yael Shemla; Itamar Simon; Hanah Margalit; Ofer Biham
Journal:  Biophys J       Date:  2012-04-18       Impact factor: 4.033

Review 2.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

3.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Authors:  Jeremy D Heidel; Zhongping Yu; Joanna Yi-Ching Liu; Shyam M Rele; Yongchao Liang; Ryan K Zeidan; Douglas J Kornbrust; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

Review 4.  Kinesin-5: cross-bridging mechanism to targeted clinical therapy.

Authors:  Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim
Journal:  Gene       Date:  2013-08-14       Impact factor: 3.688

5.  Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery.

Authors:  Doris Kneidinger; Mirza Ibrišimović; Thomas Lion; Reinhard Klein
Journal:  Antiviral Res       Date:  2012-04-10       Impact factor: 5.970

6.  Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.

Authors:  Chinh Chung Doan; Ngoc Trung Doan; Quang Huy Nguyen; Minh Hoa Nguyen; Minh Si Do; Van Dong Le
Journal:  Iran Biomed J       Date:  2015

7.  Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.

Authors:  Chung Chinh Doan; Long Thanh Le; Son Nghia Hoang; Si Minh Do; Dong Van Le
Journal:  Biol Res       Date:  2014-12-15       Impact factor: 5.612

8.  Dissecting systemic RNA interference in the red flour beetle Tribolium castaneum: parameters affecting the efficiency of RNAi.

Authors:  Sherry C Miller; Keita Miyata; Susan J Brown; Yoshinori Tomoyasu
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.